FDA Approves First Mesenchymal Stromal Cell Therapy to Treat Steroid-refractory Acute Graft-versus-host Disease
The U.S. Food and Drug Administration approved Ryoncil remestemcel-L-rknd, an allogeneic donor bone marrow-derived mesenchymal stromal cell therapy indicated for the treatment of steroid-refractory acute graft-versus-host disease SR-aGVHD in pediatric patients 2 months of age and older.